^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
2131 Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
Published date:
11/04/2020
Excerpt:
CONTRADICTING EVIDENCE: These results confirm the favourable outcome of patients with MYC and BCL-2 and/or BCL-6 rearrangements or gene ICN with R-DA-EPOCH therapy.
Secondary therapy:
EPOCH
Source:
Title:
DOSE-ADJUSTED EPOCH AND RITUXIMAB (DA-EPOCH-R) FOR THE TREATMENT OF DUAL EXPRESSOR AND DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, MULTICENTER ITALIAN STUDY
Published date:
06/12/2020
Excerpt:
Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease with as many as one-third of cases overexpressing MYC and BCL2 proteins (Dual Expressor Lymphoma, DEL)...A series of 123 consecutive pts with biopsy proven diagnosis of DEL (cut-off values of ≥40% for MYC and ≥50% for BCL2), DEL-Single Hit (DEL-SH, i.e., with a rearrangement of either MYC or BCL-2), or DEL-DH were treated with 6 cycles of DA-EPOCH-R....DA-EPOCH-R is an effective treatment for DEL and DEL-SH whereas inferior results were observed in the DEL-DH subgroup.
Secondary therapy:
EPOCH
